10 15 Associates Inc. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 4.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 195,806 shares of the biopharmaceutical company’s stock after buying an additional 7,604 shares during the period. Pfizer makes up 2.0% of 10 15 Associates Inc.’s holdings, making the stock its 19th largest position. 10 15 Associates Inc.’s holdings in Pfizer were worth $6,894,000 as of its most recent filing with the SEC.
A number of other institutional investors have also made changes to their positions in PFE. V Wealth Management LLC purchased a new stake in shares of Pfizer during the first quarter worth $272,000. Rhenman & Partners Asset Management AB boosted its stake in shares of Pfizer by 8.4% in the first quarter. Rhenman & Partners Asset Management AB now owns 475,000 shares of the biopharmaceutical company’s stock worth $14,079,000 after buying an additional 37,000 shares in the last quarter. Traynor Capital Management Inc. boosted its stake in shares of Pfizer by 0.9% in the first quarter. Traynor Capital Management Inc. now owns 27,790 shares of the biopharmaceutical company’s stock worth $823,000 after buying an additional 254 shares in the last quarter. Private Trust Co. NA boosted its stake in shares of Pfizer by 2.5% in the first quarter. Private Trust Co. NA now owns 114,956 shares of the biopharmaceutical company’s stock worth $3,406,000 after buying an additional 2,776 shares in the last quarter. Finally, Sigma Planning Corp boosted its stake in shares of Pfizer by 9.9% in the first quarter. Sigma Planning Corp now owns 88,504 shares of the biopharmaceutical company’s stock worth $2,623,000 after buying an additional 7,972 shares in the last quarter. 69.65% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.27% during mid-day trading on Friday, reaching $33.56. The company’s stock had a trading volume of 14,819,706 shares. Pfizer Inc. has a 52-week low of $28.25 and a 52-week high of $37.39. The firm’s 50 day moving average is $34.29 and its 200-day moving average is $34.19. The company has a market capitalization of $203.56 billion, a PE ratio of 29.75 and a beta of 0.86.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company had revenue of $13.10 billion for the quarter, compared to the consensus estimate of $13.01 billion. During the same quarter in the previous year, the business earned $0.56 EPS. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post $2.46 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio is presently 95.24%.
A number of equities research analysts have weighed in on PFE shares. Jefferies Group set a $41.50 price objective on Pfizer and gave the company a “buy” rating in a research note on Thursday, July 14th. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price objective for the company in a research note on Tuesday, August 2nd. JPMorgan Chase & Co. set a $40.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Wednesday, August 3rd. Argus reiterated a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a research note on Tuesday. Finally, Credit Suisse Group AG reiterated an “outperform” rating and issued a $40.00 price objective on shares of Pfizer in a research note on Monday, August 22nd. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.